@euclises.com
Euclises Pharmaceuticals develops novel COX-2 inhibitors for the effective treatment of cancers in the lungs, colon, and pancreas.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Euclises Pharmaceuticals, Inc. As a clinical stage company, we are at the forefront of developing groundbreaking oral, small-molecule drugs that specifically target COX-2, aiming to disrupt the tumor microenvironment and eradicate cancer cells. Our flagship molecule has exhibited remarkable results as a monotherapy, effectively slowing tumor growth and achieving complete tumor regression when combined with immune checkpoint inhibitors.
By eliminating COX-2/PGE-2 mediated tumor immune evasion, we are able to enhance the therapeutic effect of these inhibitors. Moreover, our research has demonstrated added antitumor effects when combined with other targeted agents such as EGFR inhibitors, effectively shutting down resistance pathways. Driven by our mission to improve the efficacy of current immuno-oncology therapies and EGFR inhibitors, we are committed to advancing these novel molecules through rigorous clinical trials.
With a team of experienced pharmaceutical veterans at the helm, each with a proven track record in developing clinical candidates and marketed drugs, Euclises is poised to redefine cancer treatment and expand the horizons of patient care. Trust Euclises to lead the way in the fight against cancer
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories